

Ref: FOI/2025/10688

Date Received: 17th April 2025

Response Due: 20th May 2025

Date: 2nd May 2025

Dear Sir/Madam

With reference to your request for information received on 17th April 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

1. **Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.**
77 patients. If we do not treat a patient, they are referred to the Christies and Manchester Royal Infirmary.
2. **Of the multiple myeloma patients treated over the past 6 months, how many were treated with the following:**
 - **Any other systemic anti-cancer therapy** = x1 MPT, x2 cyclophosphamide oral as support to lenalidomide immunotherapy and x2 high dose dex.
 - **Belantamab Mafodotin [Blenrep]** = 0.
 - **Belantamab Mafodotin [Blenrep] with bortezomib and dexamethasone** = 0.
 - **Belantamab Mafodotin [Blenrep] with pomalidomide and dexamethasone** = 0.
 - **Bortezomib [Velcade] monotherapy or with dexamethasone** = 0.
 - **Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)** = 2.
 - **Bortezomib, thalidomide and dexamethasone [VTD]** = 0.
 - **Carfilzomib [Kyprolis] and dexamethasone** = 1.
 - **Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone** = 0.
 - **Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone** = 10.
 - **Daratamumab [Darzalex] monotherapy** = 6.
 - **Daratamumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)** = 21.

- Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) = 7.
- Elranatamab = 2.
- Idecabtagene vicleucel [Abecma] = 0.
- Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) = 0.
- Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd) = 6.
- Lenalidomide [Revlimid] and dexamethasone = 9.
- Lenalidomide [Revlimid] monotherapy = 15.
- Panobinostat in combination with Bortezomib and Dexamethasone = 0.
- Pomalidomide [Imnovid] and dexamethasone = 2.
- Selinexor and dexamethasone = 0.
- Selinexor, Bortezomib [Velcade] and dexamethasone = 0.
- Talquetamab = 0.
- Teclistamab [Tecvayli] = 0.

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,



Gary Masterman
Associate Director of Pharmacy (Governance Assurance)

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111